{"id":"W2946948895","doi":"10.1016/j.jaad.2019.05.080","title":"Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study","year":2019,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Maruho; Janssen Biotech; Chugai Pharmaceutical; Ortho Dermatologics; LEO Pharma; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Dermira; Allergan; Regeneron Pharmaceuticals; National Institutes of Health; Vanda Pharmaceuticals; National Psoriasis Foundation; Pfizer; Celgene; Novartis; AbbVie; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Sanofi; MedImmune; Merck; Genentech; Coherus Biosciences; Valeant Pharmaceuticals International; Boehringer Ingelheim; Amgen; Eli Lilly and Company","keywords":"Medicine; Dermatology Life Quality Index; Adalimumab; Interquartile range; Placebo; Psoriasis; Confidence interval; Quality of life (healthcare); Odds ratio; Randomized controlled trial; Psoriasis Area and Severity Index; Internal medicine; Surgery; Dermatology; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002734349,0.002183362,0.006914039,0.0006402025,0.0006913,0.001848158,0.001357061,0.002986403,0.007730588],"category_scores_gemma":[0.003184298,0.001020764,0.004018213,0.0006798154,0.001577946,0.001536821,0.0006596888,0.003947071,0.0008256492],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009655926,"about_ca_system_score_gemma":0.0008006907,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001426863,"about_ca_topic_score_gemma":0.001838476,"domain_scores_codex":[0.9980906,0.001029196,0.0001569082,0.0003593696,0.0001570832,0.0002068766],"domain_scores_gemma":[0.9976538,0.0009197838,0.0006332736,0.0001847087,0.0001669656,0.0004414977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9925305,0.00134434,0.0005302365,0.0005256154,0.001801059,0.00001487983,0.00001297186,0.00008659191,0.0003282178,0.00003666144,0.000163651,0.00262525],"study_design_scores_gemma":[0.97774,0.01696882,0.002487338,0.00004804182,0.002122449,0.00001508946,0.00001957864,0.000204293,0.00008789547,0.00008609626,0.0002041042,0.00001632013],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9708273,0.01977758,0.0008219725,0.0007918746,0.001061301,0.002527147,0.0016252,0.0001017507,0.00246588],"genre_scores_gemma":[0.9861615,0.00528754,0.001006742,0.001012672,0.001085633,0.002435639,0.00101768,0.0000207751,0.001971793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007730588,"threshold_uncertainty_score":0.02586132,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0108444682620287,"score_gpt":0.2707372972748238,"score_spread":0.2598928290127951,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}